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Abstract.
In this special issue about biofactors causing cognitive
impairment, we present evidence for and discuss two such
biofactors. One is excess copper, causing neuronal toxicity.
The other is zinc deficiency, causing neuronal damage. We
present evidence that Alzheimer’s disease (AD) has become
an epidemic in developed, but not undeveloped, countries
and that the epidemic is a new disease phenomenon,
beginning in the early 1900s and exploding in the last 50
years. This leads to the conclusion that something in the
developed environment is a major risk factor for AD. We
hypothesize that the factor is inorganic copper, leached
from the copper plumbing, the use of which coincides with
the AD epidemic. We present a web of evidence supporting
this hypothesis. Regarding zinc, we have shown that
patients with AD are zinc deficient when compared with
age-matched controls. Zinc has critical functions in the
brain, and lack of zinc can cause neuronal death. A
nonblinded study about 20 years ago showed considerable
improvement in AD with zinc therapy, and a mouse AD
model study also showed significant cognitive benefit from
zinc supplementation. In a small blinded study we carried
out, post hoc analysis revealed that 6 months of zinc
therapy resulted in significant benefit relative to placebo
controls in two cognitive measuring systems. These two
factors may be linked in that zinc therapy significantly
reduced free copper levels. Thus, zinc may act by
lowering copper toxicity or by direct benefit on neuronal
health, or both.
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1. Introduction
In this article, I will briefly describe the Alzheimer’s disease
(AD) and the epidemiology of AD. Then, I will present evidence
for and discuss two biofactors that I believe are contributing to
cognition loss in AD. These factors are excessive ingestion of
inorganic copper from drinking water and zinc deficiency.
AD was first described in 1906 and first published in
1907 [1] by Dr. Alois Alzheimer and the disease has since
borne his name. It occurs in elderly people and usually
begins with memory loss, during which time it is often called
mild cognitive impairment (MCI). At least 80% of patients
with MCI develop full-blown AD, at the rate of about 15%
per year. As the AD disease progresses over time, cognition
decreases, and gradually the patient loses functional capa-
bilities and usually becomes dependent on a caregiver.
Diagnosis can only be certain at autopsy, where the
brain is found to have extracellular amyloid plaques, consist-
ing primarily of polymers of b-amyloid, and intracellular
neurofibrillary tangles, consisting primarily of tau protein,
the two pathologic hallmarks of AD. However, clinicians
specializing in AD have become increasingly good at making
the diagnosis and are over 90% correct, while the patients
are still living. A key factor is to exclude other causes of
cognition loss, primarily vascular dementia, the other com-
mon cause of dementia. This is done by finding that the
major risk factors for atherosclerotic vascular disease, such
as hypercholesterolemia, hypertension, and diabetes, are
missing or have been well controlled.
Developed countries are experiencing an epidemic of
AD. In the United States, the prevalence of AD in people
older than 60 years is 10%, in people older than 70 years is
20%, and in people older than 80 years is 30%. The current
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US case load of AD is 5.6 million people, with an equal num-
ber with MCI, which usually converts to AD [2]. The prevalence
is increasing rapidly. For example, in 1982, there were
650,000 cases diagnosed with AD in the United States. With
the population present then, at today’s rate, there should
have been 5.2 million cases. This increase is often attributed
to a larger population of older people and to better diagnosis;
however, I believe there is more to it than that, as I’ll discuss.
The major hypothesis for the pathogenesis of AD might
be called the ‘‘amyloid hypothesis’’ [3]. Because amyloid pla-
que formation is so intimately tied in with AD, it is thought
that these plaques are somehow toxic to neurons. A key
part of this hypothesis is that there is evidence that oxidant
damage occurs in the brains of patients with AD, and amy-
loid plaques and neurofibrillary tangles generate toxic oxi-
dant radicals, particularly in the presence of excess copper
or iron [4].
There are several known risk factors for developing AD.
The most dominant one is age, as can be seen by the
increasing prevalence with increasing age, as previously dis-
cussed. A second risk factor is having the E4 allele of apoli-
poprotein E [5]. Having one E4 allele increases risk, and hav-
ing two increases risk further. Elevated homocysteine level,
a known risk factor for atherosclerosis, is also a risk factor
for AD [6]. Moreover, having certain hemochromatosis alleles
[7] and certain transferrin alleles [8] increases risk of AD.
This latter may fit with the oxidant stress part of AD causa-
tion, as these are ‘‘iron management’’ alleles, and excess
iron causes increased oxidant stress. Another risk factor
appears to be fat in the diet. Grant [9] has shown that there
is a correlation between fat in the diet and AD prevalence
across a large number of countries.
2. A brief history of the epidemiology
of AD
Alzheimer first published on AD in 1907 [1]. The evidence is
clear that AD was very rare before that in the 1800s and af-
ter that through the early part of the 1900s. Good evidence
of this is provided by various authors who wrote extensively
on the relevant topics during this period. First, there is
Osler, who along with colleagues, wrote seven volumes on
all the human diseases known, including the seventh volume
on diseases of the brain, published in 1892 and republished
in 1907 [10]. There is no mention of an AD-like disease.
Gowers, a neurologist, published extensively on brain dis-
eases, publishing a textbook on this topic in 1888 [11], and
did not describe an AD-like disease. Freud et al. wrote
extensively from 1895 to 1939 on mental illnesses, his writ-
ings collected and published in 1966 [12], and no mention of
an AD-like disease. Finally, there is Boyd, a pathologist, who
wrote several editions of a textbook of pathology, the last
published in 1938 [13], and he did not report seeing amyloid
plaque structures and neurofibrillary tangles, hallmarks of
AD brain pathology, in brains at autopsy.
Some have said that perhaps there were not enough
old people back in the 1800s and early 1900s to allow AD to
develop with any frequency. However, Waldman and Lamb
[14] have shown that in France in 1911, half the population
lived to age older than 60 years. I have reviewed the US
census figures for 1900 and found that there were 3.2
million people older than 60 years, and at today’s rate,
there should have been 36.3 thousand AD cases in the
United States, plenty of cases to have been present in clinics
and at autopsy.
Another common opinion is that AD was considered
part of normal aging, just a part of normal senile dementia,
and that no one took special note. This view could conceiv-
ably explain the absence of AD in the writings of the clini-
cians (Osler, Gowers, and Freud); however, it does not
explain the absence of observing AD-type pathology in
brains at autopsy (Boyd).
It appears that the AD epidemic began to take off
around 1950, after the end of World War II, and that the
prevalence has been increasing ever since, but mostly in
developed countries. Undeveloped countries, such as those
in Africa, India, and South America, retain a low prevalence.
Developed countries, such as the United States and those in
Europe, are sharing in the epidemic. Japan, a developed
country, is interesting as it retains a low prevalence [15].
However, when Japanese migrate to Hawaii, they develop
the higher prevalence seen in developed countries [16].
The above description of AD epidemiology suggests
that there is something new in the environment of devel-
oped countries, not shared by Japan, which is increasing the
risk of AD. Of the various risk factors discussed earlier, only
increasing fat in the diet in developed countries, because of
increasing meat consumption, is a possible environmental
explanation for the epidemic. In my opinion, a high-fat diet
is one explanatory risk factor. However, I think it works in
conjunction with a second risk factor, increasing ingestion of
inorganic copper, to greatly enhance the prevalence of AD.
3. Copper toxicity and cognition
loss in AD
First, it is interesting that all the molecules involved in amy-
loid plaque formation and neurofibrillary tangles bind cop-
per. b-Amyloid, the critical part of amyloid plaques, binds
copper [17,18], as does the amyloid precursor protein
[19,20], from which b-amyloid is cleaved. b-Secretase, the
enzyme that cleaves off the b-amyloid, binds copper [4], as
does tau protein [21], the protein that is critical in the forma-
tion of neurofibrillary tangles, which along with amyloid pla-
ques, is the other pathologic hallmark of the AD brain.
Second, the genetic and biochemical risk factors can
all be tied in to a copper causation hypothesis. ApoE4 lacks
copper binding because it lacks cysteine, whereas ApoE3
has one copper binding site and ApoE2 has two copper bind-
ing sites. Risk of AD is lowest with the more ApoE2 alleles,
next lowest with the more ApoE3 alleles, and highest with
the more ApoE4 alleles [5]. The ApoE proteins, if they bind
copper, may help to remove copper from the brain. Next,
homocysteine binds copper, and the complex can oxidize
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cholesterol to molecules toxic to neurons [6,22]. Finally, if
certain hemochromatosis and transferrin alleles [7,8]
increase iron toxicity, iron is toxic because of generating oxi-
dant radicals, which is the same mechanism as copper toxic-
ity. Thus, increased iron would supplement increased copper,
in terms of toxicity in the brain.
An epiphany about our thinking on copper causation of
AD occurred in 2003 when Sparks and Schreurs [23] pub-
lished their landmark article on copper added to the drink-
ing water of an AD rabbit model. To cause the rabbits to
develop AD-like disease, they are fed with a high cholesterol
diet. It turned out that when distilled water rather than tap
water was used, almost no disease occurred. Both AD-type
brain pathology and cognition loss were minimal. Investiga-
tion established that it was trace amounts of copper in the
tap water that made all the difference. When 0.12 ppm cop-
per was added to the distilled water used for drinking water,
AD-type brain pathology and cognition loss were severe.
This work has been replicated in other AD animal models,
including the mouse model, in which the diet is not enriched
with cholesterol or fat [24]. It has also been replicated by
another group [25]. For reference, the Environmental Protec-
tion Agency (EPA) allows up to 1.3 ppm copper in human
drinking water in the United States, over 10 times the
amount that causes AD disease in the animal models.
Dr. Rosanna Squitti et al. in Italy have provided key
data that indicate copper toxicity is playing an important
role in the pathogenesis of AD. They have studied blood
‘‘free copper’’ levels in AD and find it elevated when com-
pared with age-matched controls [26]. About 60–65% of cop-
per in the blood is safely covalently bound to ceruloplasmin,
a copper-containing protein secreted by the liver. The other
35–40% of copper is loosely bound to albumin and various
small molecules in the blood, and is called ‘‘free copper’’
because it is more freely available for cellular uses. It is also
the potentially toxic copper of the blood, particularly if the
free copper pool becomes expanded, as it does in the inher-
ited disease of copper accumulation and copper toxicity, Wil-
son’s disease [27]. To reduce the liver and brain injury that
occurs in this disease, it is critically important to reduce the
free copper pool.
Squitti et al. have not only found that this potentially
toxic-free copper pool is increased in size in patients with
AD [26] but also that higher the level of free copper, the
lower is the cognition in patients with AD [28], and the
higher the level of free copper, the greater is the loss of
cognition over a given period of time [29]. Furthermore, they
found that in a group of elderly women who did not have
AD, the free copper pool was negatively correlated with
cognition, just as in AD [30].
This last study by the Squitti group takes us into
effects of copper in the normal, non-AD, population. Very
interesting work in this population was done by Morris et al.
in Chicago [31]. They did a large study of nutritional intake
and observed the relationship of specific nutrients to cogni-
tion loss over several years. They found that those in the
highest quintile of copper intake, if they also ate a high-fat
diet, lost cognition at six times the rate of other groups.
These people were in the highest quintile of copper intake
by virtue of taking vitamin/mineral supplements, each pill of
which contains 1–3 mg of copper.
The study of Morris et al. [31] should stir memories of
the study by Sparks and Schreurs [23] in that both found
copper plus a high-fat/-cholesterol diet affected cognition. In
addition, these two studies have something else in common:
both involve exposure to a kind of copper we call inorganic
copper. Copper in food is bound to proteins, and we call it
organic copper. The copper-binding protein is digested to
polypeptides and amino acids, and the bound copper is
taken up by a copper transporter called Ctrl [32] in intestinal
cells. This copper ends up in the liver for processing, being
safely routed into various copper handling pathways, includ-
ing covalent incorporation into the ceruloplasmin molecule.
In contrast, I believe at least part of ingested inorganic cop-
per is handled differently, bypasses the liver, and directly
enters the free copper pool in the blood, with potential
toxicity to the brain.
Findings from studies we did in Wilson’s disease sup-
port our claim that at least some ingested inorganic copper
bypasses the liver and enters the blood directly. When we
administer 64Cu orally as an inorganic salt as part of a 64Cu
test we do in Wilson’s disease, some of the labels are found
in the blood as soon as 1 h, too soon to have been proc-
essed by the liver [33].
So, could the toxicity of inorganic copper explain the
epidemic of AD in developed countries beginning about 1950
and exploding ever since? Yes, because the epidemic coin-
cides very well with the use of copper plumbing tube in
developed but not undeveloped countries. Copper plumbing
was initiated in the early 1900s, but because of two world
wars did not see great use until about 1950, at which time it
saw explosive use, such that now, 90% or so of US homes
uses copper plumbing. Remember earlier on, we talked
about Japan being an exception to the epidemic of AD in the
developed countries [15], but when Japanese moved to
Hawaii, they developed the increased incidence of AD seen
elsewhere in the developed world [16]? It turns out that
Japan, alone among developed countries, shunned the use
of copper plumbing, apparently because of fear of copper
toxicity. On the other hand, copper plumbing is widely used
in Hawaii. Therefore, the epidemiologic data fit the hypothe-
sis of use of copper plumbing being associated with the AD
epidemic quite well.
Of course, association does not prove causation. To
move to causation, we have to connect the link of the study
of Sparks and Schreurs [23] of trace amounts of copper
(0.12 ppm) in drinking water causing AD in animal models to
whether the use of copper plumbing results in enough cop-
per in human drinking water to be potentially toxic. Is there
any current data on copper levels in human drinking water
in developed countries? Yes, through coincidence, I collected
data on copper levels in drinking water from 280 North
American households, as a part of an effort to avoid exces-
sive ingestion of copper in my patients with Wilson’s dis-
ease. These samples were collected in trace element free
containers and shipped to our Ann Arbor Laboratory for
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assay. The following summarizes the results: 1.8% of the
samples contained more copper than the EPA limit of
1.2 ppm; 31% of the samples contained more copper than
caused AD worsening in the animal models (0.12 ppm); 28%
of the samples contained 0.01 ppm, or less (a level I regard
as trivial enough to be safe); and 41% of the samples con-
tained between 0.01 and 0.1 ppm copper, levels of unknown
safety. Thus, a total of 72% of the samples contained unsafe
levels of copper according to the animal models or were of
unknown safety.
So, the hypothesis of ingestion of inorganic copper as
at least partially causative of AD fits the data nicely. First,
there is the explosive epidemic of AD and the explosive use
of copper plumbing coinciding in developed countries in the
latter part of the 20th century, except for Japan, who did not
share in either. Then, there is the data that low levels of
copper in drinking water worsen AD in animal models. Then,
there is our data that levels of copper in the drinking water
in North American households is well above safe limits,
based on the animal models, in a large percentage of the
samples. Then, there is our data that ingested inorganic cop-
per is at least in part, allowed to enter the blood free copper
pool directly. Finally, there is the Squitti data [26,28,29],
identifying an elevation of blood free copper as intimately
associated with cognition loss in AD. Beyond this, there is
the Morris et al. [31] data, suggesting that ingestion of inor-
ganic copper in the form of supplement pills may also be
damaging cognition.
All in all, the hypothesis that inorganic copper inges-
tion is playing a causal role in AD is very well supported. To
be clear, I do not believe that it is the whole story. Ingestion
of a high-fat diet also appears to be causative [9], as does
involvement of risk factors such as age, ApoE4 genotype [5],
and homocysteine levels [6]. However, I believe that inges-
tion of inorganic copper coupled with a high-fat diet sets the
stage on which the others risk factors act.
4. Zinc deficiency and cognition
loss in AD
Based on serum zinc levels, patients with AD are clearly zinc
deficient. This was first shown in a sample of patients with
AD from Albany, in comparison to age-matched controls [34].
In such a study, it is important to wash out the effect of any
vitamin/mineral supplements (which always contain zinc).
The patients in the Albany study had supplements stopped
1 month prior to study. Zinc deficiency in AD has also been
identified by another group [35]. Serum zinc levels decline
with aging, but patients with AD, on average, decline more
rapidly, thus making them zinc deficient when compared
with age-matched controls [34].
These studies demonstrate that patients with AD are
zinc deficient by serum zinc status; however, what about the
brain, is it suffering from inadequacy of zinc, and if so, is
that at least a partial explanation for cognition loss in AD?
Very interesting data and insight on these questions are
provided in a publication by Adlard et al. [36]. First, these
authors studied zinc transporter-3 (ZnT3) knock out (KO)
mice. ZnT3 is the zinc pump that loads synaptical vesicles
with zinc. These vesicles are secreted into the synapse and
the released zinc plays many important neuronal functions.
The ZnT3 KO mice exhibit defects in learning and memory at
6 months of age, and the authors suggest that these synap-
tically zinc-deficient mice provide ‘‘a phenocopy for the
synaptic and memory deficits of AD.’’
These authors [36] also found that ZnT3 level
decreased with aging in brains of both mice and humans
and decreased even further with aging in the brains of
patients with AD, when compared with age-matched
controls. They also point out that the extracellular amyloid
plaques in AD brain are avid zinc binders, further depleting
available zinc for neurons.
One of the important neuronal functions of zinc is to
limit glutamate neuronal firing [37]. Glutamate excitotoxicity
damages neurons and may be a problem in many neurode-
generative diseases. Zinc also plays a role in NMDA neurons
where it binds to a NMDA receptor required for functioning.
Another important mechanism may be zinc’s capacity to
inhibit calcineurin [38]. Increased neuronal calcineurin activ-
ity as a causative factor in AD is postulated, because it is
increased in AD brain, it affects many downstream biochemi-
cal functions adversely. Calcineurin activity is increased by
exposure to b-amyloid and inhibited by zinc.
From the above, it seems increasingly likely that neuro-
nal zinc deficiency is playing an important, perhaps a key,
role in decreasing neuronal function and increasing damage,
leading to cognition loss in AD. It is possible to put the two
parts of our hypothesis together as follows. Perhaps excess
copper and copper toxicity lead to amyloid plaque develop-
ment and the plagues trap increasing amounts of zinc. This
zinc depletion effect, together with the zinc depletion of
aging, exaggerated in AD, and the loss of ZnT3 function with
aging, exaggerated in AD, leads to severe neuronal zinc defi-
ciency and neuronal damage. The damage could come about
through the mechanisms already discussed.
Based on the above, it is reasonable to hypothesize
that zinc therapy might be helpful in AD. Interestingly, zinc
was tried as a therapy, both orally and parenterally, in
patients with AD in 1992 [39]. Substantial improvement in
cognition was reported, but of course these were uncon-
trolled studies. More recently, a study of zinc therapy in a
mouse model of AD also reported improved cognitive
performance when compared with placebo controls [40].
Based on all this information, Adeona Pharmaceuticals
Inc. sponsored a controlled study of zinc therapy in mild to
moderate AD. We used a new zinc formulation that we had
developed at Adeona. To give some background on zinc ther-
apy, I had developed zinc acetate as a therapy for Wilson’s
disease, an inherited disease of copper accumulation and
copper toxicity. Zinc acts by blocking intestinal copper
absorption, perhaps by inducing intestinal metallothionein,
which binds copper and takes the copper out into the stool
as intestinal cells are shed. I found that I had to give the
zinc away from food to be effective, because many substan-
ces in food bind zinc and prevent its absorption. I found that
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I had to give about 50 mg of elemental zinc at least twice a
day to effectively block copper absorption. I ended up
recommending 50 mg three times a day, as a safety factor. I
did numerous studies showing long-term control of copper
levels and copper toxicity by zinc therapy; the data are pre-
sented in a series of 18 papers on zinc therapy of Wilson’s
disease. Paper XV of this series nicely summarizes much of
the data and presents long-term follow-up information [27].
Zinc acetate therapy was approved for Wilson’s disease by
the Federal Drug Administration (FDA) in 1997 and is the
treatment of choice for Wilson’s disease.
Older therapies for Wilson’s disease have many prob-
lems. Penicillamine has a long list of side effects [41] and
makes up to half of neurologically presenting patients
worse, many of whom do not recover [42]. Trientine shares
some of the side effects of penicillamine, but with a lower
frequency. However, it makes about 25% of neurologically
presenting patients worse, and many do not recover [43]. As
zinc is rather slow acting for initial treatment of neurologi-
cally presenting patients, we developed tetrathiomolybdate
(TM) for treating these patients. TM is a novel anticopper
agent that works by binding copper and protein in a tripar-
tite complex. It is very effective for treating neurologically
presenting Wilson’s disease patients [43], but so far has not
gained FDA approval. This leaves zinc therapy as the best
choice for the neurologically presenting Wilson’s disease
patients.
Although zinc therapy was very effective and is the
maintenance therapy of choice for Wilson’s disease, it had
two problems. One was that given on an empty stomach, as
zinc must be to be effective, it was irritating to the stomach
in many patients. The zinc acetate capsules, dissolving
quickly, release a high concentration of salt in a small region
of the stomach, which is irritating in upward of 50% of
patients. The other problem is that the zinc dose must be
given two to three times a day to maintain elevated blood
zinc levels, enough of the time to block intestinal absorption
of copper, the mechanism of zinc therapy in Wilson’s dis-
ease. This multiple dosing, particularly when each capsule
must be separated from food by 1 or 2 h, is a big nuisance
for patients on long-term therapy.
The new Adeona zinc formulation, called reaZin, is gas-
troretentive and contains an agent that releases zinc slowly.
Thus, gastric irritation is minimized, and the slow release
results in many hours of plasma zinc elevation, thus allowing
one a day dosing. The single daily zinc dose was 150 mg/
day, separated from food, in the AD study.
The study was designed to recruit 60 patients, ran-
domly assigned equally to zinc or matching placebo, and
treated for 6 months. Patients were diagnosed by standard
clinical, functional, and Alzheimer’s Disease and Related Dis-
orders Association criteria. AD was mild to moderate with a
Clinical Dementia Rating (CDR) of 0.5–1.5. Patients were
monitored to prevent clinical copper deficiency. Only one
patient during the 6 months of therapy had to have zinc
dose lowered because of a decreasing copper status. The
endpoints were improvement in serum zinc, reduction in
serum free copper, and benefit in cognition in zinc treated
versus controls. Cognition was measured by the Alzheimer’s
Disease Assessment Scale for Cognition (ADAS-Cog), the
Mini Mental State Examination (MMSE), and the Clinical
Dementia Rating Scale, Sum of Boxes (CDR-SOB). Dr. Diana
Pollack, of Ptak Alzheimer’s Center, Morton Plan Neuro-
science Institute, Morton Plant Hospital, Clearwater, FL, was
the principal investigator.
As presented by poster at the 63rd Annual Meeting of
the American Academy of Neurology in Hawaii on April 14,
2011, by Dr. Pollack, serum zinc was greatly improved by
zinc therapy, and serum-free copper was significantly
reduced (Table 1). All three of the cognition scoring tests
showed better scores in the zinc-treated group than the pla-
cebo group; however, none were statistically significant,
although CDR-SOB was close, at P ¼ 0.1 (Table 2).
Later, post hoc analysis presented at the American Col-
lege of Nutrition Meeting in Morristown, NJ, in November,
2011, by Dr. Pollack revealed very interesting facts. First,
what zinc was doing was stabilizing cognition while placebo
patients deteriorated. Second, the deterioration in the pla-
cebo patients was very age dependent, the older patients
deteriorating much more rapidly. Seeing this, we reanalyzed
Table 1
reaZin AD trial efficacy results: Zn 1 Cu endpoints
Baseline
n ¼ 45
6 months
n ¼ 36 P
Serum zinc, lg/dl
Treatment 76.4 151.8 0.002
Placebo 70.8 75.3 0.153
Serum-free Cu, lg/dl
Treatment 37.0 30.8 0.0042
Placebo 34.8 34.9 0.486
Table 2
reaZin AD trial efficacy results: Cognitive score endpoints (n 5 42)
 All three cognitive scoring systems showed less deterioration in the reaZin versus the placebo group
ADAS-Cog MMSE CDR-SOB Global (composite of all three)
P values 0.36 0.42 0.10 0.15
 Conclusion:
a) The finding that all three cognitive scoring systems showed advantage in the treated group is encouraging.
b) None showed statistical significance, although CDR-SOB is close.
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the data, limiting it to those patients aged 70 years and
older. This analysis included 14 zinc-treated patients versus
15 placebo patients and revealed statistically significant
better cognition scores in the zinc-treated patients versus
controls in ADAS-Cog (P ¼ 0.037) and CDR-SOB (P ¼ 0.032),
with near significant results in MMSE (P ¼ 0.07; Table 3).
As this analysis was post hoc, it cannot be used as a
definitive proof that zinc therapy is effective in preserving
cognition in AD. Post hoc analyses are weaker than pre-hoc
hypothesis testing, because when the data are looked at
in multiple ways, there is an increasing likelihood that
statistical significance is due to chance. To a certain extent
this depends on how many different post hoc analyses are
done. In our case, it was two (evaluating the different
sites separately, and this age analysis), and therefore, the
statistics are not badly weakened. Thus, we consider these
data of zinc therapy efficacy as strong evidence, and Adeona
is planning to sponsor another study to provide definitive
proof.
Assuming the repeat study confirms that zinc therapy
preserves cognition in AD, it means that lack of zinc is a
very significant factor in cognition loss in AD.
5. Summary
In this article, we have put forward the concepts that inges-
tion of inorganic copper in drinking water and zinc deficiency
both contribute to cognition loss in AD. Assuming that both
of these concepts are correct, it is possibly useful, in trying
to understand AD pathogenesis, to try to put them together.
We have already suggested one possible link that of excess
extracellular free copper causing amyloid plaque formation,
and the plaques binding zinc, worsening neuronal zinc defi-
ciency. There may also be a connection between efficacy of
zinc therapy and copper toxicity as follows.
There is evidence of increased oxidant damage in the
AD brain. Copper is probably toxic through an oxidant
damage mechanism. For example, copper binding to amyloid
plaques causes increased generation of oxidant radicals.
Increased zinc in the brain may allow zinc to displace copper
from sites where copper is generating oxidant radicals, and
thus reduce the damage from copper. We know that zinc
therapy is significantly lowering blood free copper in
patients with AD, and this may be occurring in the brain as
well, thus limiting copper toxicity in this manner. Zinc could
be doing these things, interacting with copper, while also
independently stabilizing neuronal health.
Our data so far indicate that zinc therapy does not
improve cognition, but rather stabilizes it and at least par-
tially prevents the cognition loss occurring otherwise. We
should know within 1–2 years, when our definitive study is
completed, whether this is proven, which will decide
whether all patients with AD should be on zinc therapy.
In the meantime, what should people do about copper.
The evidence we have put together suggests that inorganic
copper ingestion is partially causal of AD. Everyone has to
decide for themselves whether this evidence is strong
enough to warrant action. For those who wish to act, we rec-
ommend throwing away all vitamin/mineral supplement pills
that contain copper. Drinking water can be tested, and if it
contains more than 0.01 ppm copper, an alternate source to
be used. A reverse osmosis device, or other device that
removes copper, can be placed on the tap that supplies
drinking water. Meat intake can be reduced, because copper
in meat is much more bioavailable than copper in nonmeat
foods. Finally, one can take zinc to reduce copper levels, but
this should be done under a physician’s supervision,
because clinical copper deficiency can occur if copper is
depleted too much.
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